Savara Inc Sample Contracts

Savara Inc – AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (August 9th, 2018)

This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), dated as of August 3, 2018, by and among Savara Inc., successor-in-interest to Aravas Inc. (the “Company”), and Robert Neville (the “Executive”).

Savara Inc – AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (August 9th, 2018)

This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), dated as of August 3, 2018, by and among Savara Inc., successor-in-interest to Aravas Inc. (the “Company”) and Taneli Jouhikainen (the “Executive”).

Savara Inc – Amendment No. 1 To the RESEARCH COLLABORATION AND LICENSE AGREEMENT Between SAVARA INC. and PARI Pharma GmbH (August 9th, 2018)

This first amendment (“Amendment No. 1”) to the Research Collaboration and License Agreement, effective as of 7th day of November 2014, between PARI Pharma GmbH, Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”) and Serendex Pharmaceuticals A/S, Slotsmarken 17, 2.tv., DK-2970 Hørsholm, Denmark (“Serendex”) (the “Agreement”), is made effective as of May 23rd, 2018 (“Amendment No. 1 Effective Date”) by and between PARI and Savara Inc. with a principal place of business at 6836 Bee Cave Road, Building 3, Suite 200, Austin, TX, 78746, United States of America (“Savara”).  PARI and Savara shall be referred to each as a “Party” and collectively as the “Parties”.

Savara Inc – AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (August 9th, 2018)

This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), dated as of August 3, 2018, by and among Savara Inc., successor-in-interest to Aravas Inc. (the “Company”), and David Lowrance (the “Executive”).

Savara Inc – 4,250,000 Shares Savara Inc. UNDERWRITING AGREEMENT (July 26th, 2018)
Savara Inc – AMENDMENT NO. 1 TO COMMON STOCK SALES AGREEMENT (June 29th, 2018)

Savara, Inc. (the “Company”) and H.C. Wainwright & Co. LLC (“HCW”) are parties to that certain Common Stock Sales Agreement dated April 28, 2017 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:

Savara Inc – SAVARA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES (June 29th, 2018)

WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;

Savara Inc – SAVARA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES (June 29th, 2018)

WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;

Savara Inc – SAVARA INC. CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (June 7th, 2018)

Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that:

Savara Inc – SAVARA INC. 2015 OMNIBUS INCENTIVE PLAN (as amended and restated on March 7, 2018) (June 7th, 2018)

Savara Inc., a Delaware corporation (f/k/a Mast Therapeutics, Inc., the “Company”), hereby establishes the amended and restated 2015 Omnibus Incentive Plan (the “Plan”), effective as of the Effective Date.

Savara Inc – Savara Inc. 2015 Omnibus Incentive Plan Non-Statutory Stock Option Grant Agreement (March 14th, 2018)

THIS NON-STATUTORY STOCK OPTION GRANT AGREEMENT (this “Agreement”), effective as of [●] (the “Grant Date”), is entered into by and between Savara Inc., a Delaware corporation (the “Company”), and [●] (the “Grantee”).

Savara Inc – Savara Inc. 2015 Omnibus Incentive Plan Incentive Stock Option Grant Agreement – Exempt Employees (March 14th, 2018)

THIS INCENTIVE STOCK OPTION GRANT AGREEMENT (this “Agreement”), effective as of [●] (the “Grant Date”), is entered into by and between Savara Inc., a Delaware corporation (the “Company”), and [●] (the “Participant”).

Savara Inc – SUBLEASE AGREEMENT (December 4th, 2017)

THIS SUBLEASE AGREEMENT (this “Sublease”) is made and entered into as of November 28, 2017, by and between SAVARA INC., a Delaware corporation (the “Sublandlord”), whose mailing address is 6836 Bee Cave Road, Suite 200, Austin, TX 78746, and CLUBESSENTIAL, LLC., a Delaware limited liability company (the “Subtenant”), whose mailing address is 4600 McAuley Place, Suite 350, Cincinnati, Ohio 45242.

Savara Inc – SUBLEASE AGREEMENT (December 4th, 2017)

THIS SUBLEASE AGREEMENT (this “Sublease”) is made and entered into as of November 28, 2017, by and between CLUBESSENTIAL, LLC, a Delaware limited liability company (the “Sublandlord”), whose mailing address is 4600 McAuley Place, Suite 350, Cincinnati, Ohio 45242, and SAVARA INC., a Delaware corporation (the “Subtenant”), whose mailing address is 6836 Bee Cave Road, Suite 200, Austin, TX 78746.

Savara Inc – Award Receipt: Award for Savara Inc. (“SAVARA”) Purposes: Funding of Phase 2a Clinical Trial for AeroVanc (a high performance inhalation powder formulation of vancomycin hydrochloride) for MRSA (the “Research Program”) Payment of Award: Up to $1.7 MM to the extent actually disbursed in accordance with Milestones Schedule in Exhibit B (the “Award”) Term: In accordance with the Projected Timing Schedule (Exhibit B) (November 30th, 2017)

We are pleased to inform you that Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit affiliate of the Cystic Fibrosis Foundation that administers clinical research, therapeutics development and drug discovery payments in order to seek a cure for or mitigation of CF on behalf of individuals with the disease, is issuing a contracted research award for the Research Program in the amount of the Award. The Research Program Plan is set forth in Exhibit A. It is required that the awardee commit matching funds for the Research Program. Each party’s obligations hereunder will commence upon the initial distribution of the Award, designated as Milestone 1 in Exhibit B. The Award is subject to the following terms, conditions and provisions of this Letter Agreement (“Agreement”):

Savara Inc – SETTLEMENT AGREEMENT (November 8th, 2017)

This Settlement Agreement is executed to witness the full, final and complete settlement between Savara and Serenova with respect to any and all disputes, claims or potential claims arising between them in regard to the payment of service fees and actual costs to TFS Trial Form Support International AB (“TFS”) and DOT World Co., Ltd. (“DOT”) in the amount of JPY 53,528,875 and related consumption taxes in the amount of JPY 1,992,600 (collectively, the “TFS Invoices”), related to the IMPALA study.

Savara Inc – SAVARA INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS (November 8th, 2017)

The Awardee has been granted an award of Restricted Stock Units (the “Award”) pursuant to the Savara Inc. 2015 Omnibus Incentive Plan (the “Plan”), each of which represents the right to receive on the applicable Settlement Date one (1) Share of common stock of Savara Inc. (the “Company”), as follows:

Savara Inc – FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (November 8th, 2017)

THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 31st day of October, 2017, by and among SILICON VALLEY BANK, a California corporation (“Bank”) and SAVARA INC. f/k/a MAST THERAPEUTICS, INC., a Delaware corporation (“Parent”), and ARAVAS INC. f/k/a SAVARA INC. a Delaware corporation (each a “Co-Borrower” and collectively “Co-Borrowers”).

Savara Inc – SECOND ADDENDUM (November 8th, 2017)

NOW, THEREFORE, IN CONSIDERATION OF THE MUTUAL CONVENANTS, AGREEMENTS AND REPRESENTATIONS HEREIN CONTAINED, THE PARTIES AGREE AS FOLLOWS:

Savara Inc – SAVARA INC. FORM OF WARRANT TO PURCHASE COMMON STOCK (October 25th, 2017)

Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [                            ] or its permitted registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [                ] shares of common stock, $0.001 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”), upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to time on or after the date hereof (the “Original Issue Date”) and through and including 5:30 P.M., New York City tim

Savara Inc – 5,250,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 775,000 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT (October 25th, 2017)
Savara Inc – Contract (August 9th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

Savara Inc – Contract (August 9th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

Savara Inc – AMENDMENT TO Warrant to Purchase COMMON Stock (August 9th, 2017)

This Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of June 26, 2017, by and between SVB FINANCIAL GROUP (“Holder”) and SAVARA INC. a Delaware corporation (“Company”).

Savara Inc – AMENDMENT TO Warrant to Purchase COMMON Stock (August 9th, 2017)

This Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of June 26, 2017, by and between LIFE SCIENCE LOANS II, LLC (“Holder”) and SAVARA INC. a Delaware corporation (“Company”).

Savara Inc – 8,421,053 Shares Savara Inc. UNDERWRITING AGREEMENT (June 2nd, 2017)
Savara Inc – CONSULTING SERVICES AGREEMENT (May 9th, 2017)

THIS CONSULTING SERVICES AGREEMENT (this “Agreement”) is made effective as of April 28, 2017 (the “Effective Date”) by and between SAVARA INC., a Delaware corporation having a principal place of business at 900 S. Capital of Texas Highway, Suite 150, Austin, Texas 78746 USA (“Savara”), and Brandi Roberts, an individual having a principal place of business at 9975 Fox Meadow Rd, San Diego, CA 92127 (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).

Savara Inc – SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (May 9th, 2017)

THIS SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (hereinafter “Agreement”) is entered into by and between Brandi L. Roberts (hereinafter “Employee”) and Mast Therapeutics, Inc. (hereinafter “Mast” or the “Company”).  Employee and Mast hereinafter are collectively referred to as the “Parties” or individually referred to as a “Party.”

Savara Inc – SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (May 9th, 2017)

THIS SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (hereinafter “Agreement”) is entered into by and between Brian M. Culley (hereinafter “Employee”) and Mast Therapeutics, Inc. (hereinafter “Mast” or the “Company”).  Employee and Mast hereinafter are collectively referred to as the “Parties” or individually referred to as a “Party.”

Savara Inc – SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (May 9th, 2017)

THIS SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (hereinafter “Agreement”) is entered into by and between Shana Hood (hereinafter “Employee”) and Mast Therapeutics, Inc. (hereinafter “Mast” or the “Company”).  Employee and Mast hereinafter are collectively referred to as the “Parties” or individually referred to as a “Party.”

Savara Inc – Contract (May 9th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

Savara Inc – LOAN AND SECURITY AGREEMENT (May 9th, 2017)

THIS LOAN AND SECURITY AGREEMENT (as amended, restated, modified or otherwise supplemented from time to time, this “Agreement”) dated as of April 28, 2017 between SILICON VALLEY BANK, a California corporation (“Bank”), and, SAVARA INC. f/k/a MAST THERAPEUTICS, INC., a Delaware corporation (“Parent”) and ARAVAS INC. f/k/a SAVARA INC. a Delaware corporation (each a “Co-Borrower” and collectively “Co‑Borrowers”), provides the terms on which Bank shall lend to Co-Borrowers and Co-Borrowers shall repay Bank.  The parties agree as follows:

Savara Inc – CONSULTING SERVICES AGREEMENT (May 9th, 2017)

THIS CONSULTING SERVICES AGREEMENT (this “Agreement”) is made effective as of April 24__, 2017 (the “Effective Date”) by and between SAVARA INC., a Delaware corporation having a principal place of business at 900 S. Capital of Texas Highway, Suite 150, Austin, Texas 78746 USA (“Savara”), and Edwin L Parsley, DO, an individual having a principal place of business at 3972 Albatross #303, San Diego, CA 92103 (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).

Savara Inc – Contract (May 9th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

Savara Inc – SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (May 9th, 2017)

THIS SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (hereinafter “Agreement”) is entered into by and between Edwin L. Parsley (hereinafter “Employee”) and Mast Therapeutics, Inc. (hereinafter “Mast” or the “Company”).  Employee and Mast hereinafter are collectively referred to as the “Parties” or individually referred to as a “Party.”